Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
简介:Inversago作为一家专业治疗,临床阶段的生物技术公司,Inversago Pharma开发了新一代外周作用大麻素-1受体(CB1)反向激动剂,用于治疗糖尿病肾病,1型和2型糖尿病,非酒精性脂肪性肝炎,肥胖并发症,高甘油三酯血症,以及纤维化适应症,如进行性纤维化 - 间质性肺疾病,包括特发性肺纤维化。Inversago分子的作用机制解...
同日,公司宣布以高达 10.75 亿美元现金收购 Inversago Pharma(简称“Inversago”);Inversago是一家基于 CB1 受体的疗法,专注于开发治疗肥胖、糖尿病和代谢紊乱相关并发症的公司,核心药物是CB1 反向激动剂INV-202。 一 Inversago公司介绍 Inversago是一家处于临床阶段的公司,是开发下一代 CB1 受体阻滞剂疗法的领...
#药闻简讯#2023 年 8 月 10 日 –诺和诺德和 Inversago Pharma 今天宣布,如果实现某些开发和商业里程碑,诺和诺德已同意以高达 10.75 亿美元现金收购 Inversago。Inversago Pharma 是一家总部位于蒙特利尔的私营开发商,开发基于 CB1 受体的疗法,用于治疗肥胖、糖尿病和代谢紊乱相关并发症。 Inversago 的收购包括该...
Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update
Inversago是一家临床前阶段的生物医药服务商,专注于开发基于大麻素1型受体(CB1)阻断的疗法,旨在为受Prader-Willi综合征(PWS)、非酒精性脂肪性肝炎(NASH)、1型糖尿病(T1D)和糖尿病肾病等代谢疾病影响的患者提供新的治疗方案,改善患者生活。 融资历程3
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Senior Vice President, Drug Development. In his position, Dr. Michael Harvey will be responsible for
Novo Nordisk has said it will be acquiring Canada-based Inversago Pharma, a specialist in metabolic disorders, in a deal worth $1.075bn. The transaction gives the Danish drugmaker access to Inversago’s lead asset, INV-202, a CB1 receptor blocker being developed to treat metabo...
诺和诺德收购代谢紊乱药物公司 Inversago Pharma,进一步增强肥胖和糖尿病产品组合。预付款金额未披露,里程碑付款高达 10.75 亿美元。 Inversago 的核心管线first-in-class口服小分子CB1反向激动剂INV-202已在临床Ib期试验中显示出减肥的潜力,正在临床II期试验作为糖尿病肾病药物进行测试。CB1常见于外周组织(包括肾脏和肝...
Inversago Pharma to Present Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions.